My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.07 +0.01 (+0.05%)
Streaming Delayed Price Updated: 3:53 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,096,482
Open 20.59
Bid (Size) 20.07 (4)
Ask (Size) 20.08 (6)
Prev. Close 20.06
Today's Range 19.69 - 20.77
52wk Range 13.40 - 26.65
Shares Outstanding 162,625,379
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth and Positive Technical Setup
ACADIA Pharmaceuticals shows strong EPS and revenue growth with a positive technical setup, making it a compelling growth stock candidate. 
Via Chartmill
Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant... 
Via MarketMinute

Performance

YTD
+7.6%
+7.6%
1 Month
-15.0%
-15.0%
3 Month
-8.3%
-8.3%
6 Month
+35.1%
+35.1%
1 Year
+33.9%
+33.9%

More News

Read More
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
From Acadia Pharmaceuticals Inc.
Via Business Wire
Earnings Scheduled For August 6, 2025
Via Benzinga
Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents an Affordable Growth Opportunity
Via Chartmill
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
Via Benzinga
Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study
Via Stocktwits
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Technical Setup for Potential Breakout
Via Chartmill
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
From Acadia Pharmaceuticals Inc.
Via Business Wire
Assessing ACADIA Pharmaceuticals: Insights From 12 Financial Analysts
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Emerges as a Top Affordable Growth Stock
Via Chartmill
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Affordable Growth Stock with Fair Valuation and High Potential
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Combines Strong Fundamentals with Bullish Technicals for Growth Potential
Via Chartmill
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia (ACAD) Q2 Revenue Rises 9%
Via The Motley Fool
Topics Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates
Via Chartmill
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 20.07
When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 10/13/25 03:53 PM ET
What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 3.26B
How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
ACADIA Pharmaceuticals Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.